Chronic Kidney Disease (CKD): Clinical Breakdown: Pathophysiology, GFR Staging Classifications, Primary Etiologies, Complications, and Therapeutic Management
A clinical reference defining CKD as abnormalities of kidney structure or function for three months or more, with the five eGFR stages, the hyperfiltration cycle, leading etiologies and systemic complications.
Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026
Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.
What we found that needs correcting
- The definition, the staging table and the hyperfiltration section are all correct, and the brief is right to put the three-month requirement in the opening sentence, since that is what separates CKD from acute kidney injury. The notes below add the second axis of staging and the treatments developed since the framework in this brief was written.
- The staging table is only half the classification. Current guidance stages CKD by cause, eGFR and albuminuria together. Albuminuria categories are A1, under 30 mg/g; A2, 30 to 300; and A3, above 300. They modify risk at every eGFR stage, and they are combined into a risk grid. Someone at stage 3a with A1 is often stable for years, while someone at stage 3a with A3 is at very high risk. Giving a stage without an albuminuria category overstates how much that stage tells you.
- Stages 1 and 2 require evidence of kidney damage, which the table implies but does not state as a rule. An eGFR of 75 with no albuminuria and no structural abnormality is not stage 2 CKD, it is normal, and people are regularly told otherwise.
- The therapeutic section is the part most in need of updating. SGLT2 inhibitors reduce progression to kidney failure and cardiovascular events in CKD with and without diabetes, and are now standard for many patients. Finerenone reduces progression in CKD with type 2 diabetes on top of ACE inhibitor or ARB therapy. GLP-1 receptor agonists have also shown kidney benefit. None appear in the brief.
- One practical point belongs with the ACE inhibitor and ARB recommendation: an expected acute fall in eGFR of up to around 30 percent follows initiation, reflecting reduced intraglomerular pressure, and it is associated with a shallower long-term decline. Patients and clinicians stop effective drugs over this, and the brief recommends the drugs without warning about it.
- ACE inhibitors and ARBs are not combined with each other, and all of these agents raise potassium, which is why potassium and creatinine are checked two to four weeks after starting or increasing a dose.
- The etiology section should include two things it omits. Repeated or severe acute kidney injury raises the long-term risk of CKD substantially and is frequently not followed up. And APOL1 risk variants, carried by a substantial minority of people of recent West African ancestry, markedly raise the risk of several kidney diseases and of faster progression.
- On measurement: United States laboratories moved to a race-free eGFR equation in 2021. The previous adjustment for Black patients systematically reported higher kidney function for the same creatinine, delaying diagnosis, referral and transplant listing. A clinical reference published now should note which equation it assumes. Cystatin C is also recommended as a confirmatory measure when the creatinine-based estimate does not fit the clinical picture.
- The complications list is accurate and could add two items: vascular calcification as the link between mineral and bone disorder and cardiovascular death, and hyperkalemia, which is the complication most likely to cause harm quickly and which is usually asymptomatic until severe.
- Finally, referral criteria would make this reference more actionable: eGFR persistently below 30, sustained decline greater than about 5 per year, albuminuria above 300 mg/g at any eGFR, persistent unexplained haematuria with proteinuria, and hypertension resistant to four or more agents. Late referral is associated with unplanned dialysis starts and worse first-year outcomes.
- Everything else is accurate: the definition as abnormalities of structure or function for three months or more with health implications; the eGFR stage boundaries as tabulated with stage 3 split into 3a and 3b; compensatory hyperfiltration and hypertrophy sustaining intraglomerular hypertension and accelerating nephron loss; diabetes and hypertension as the leading causes globally, with glomerulonephritis, polycystic kidney disease, tubulointerstitial nephritis and obstruction as secondary causes; and secondary hyperparathyroidism, normocytic anaemia from reduced erythropoietin, metabolic acidosis, fluid overload and cardiovascular disease as the systemic consequences.
Download the PDF
Our reviewed pages on this
All source documents